Orexo AB (publ) (STO: ORX)
Sweden
· Delayed Price · Currency is SEK
19.36
+0.58 (3.09%)
Jan 20, 2025, 4:54 PM CET
Orexo AB Revenue
Orexo AB had revenue of 136.50M SEK in the quarter ending September 30, 2024, a decrease of -12.56%. This brings the company's revenue in the last twelve months to 595.70M, down -5.26% year-over-year. In the year 2023, Orexo AB had annual revenue of 638.80M with 2.32% growth.
Revenue (ttm)
595.70M
Revenue Growth
-5.26%
P/S Ratio
1.12
Revenue / Employee
5.27M
Employees
116
Market Cap
668.02M
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 638.80M | 14.50M | 2.32% |
Dec 31, 2022 | 624.30M | 59.30M | 10.50% |
Dec 31, 2021 | 565.00M | -98.60M | -14.86% |
Dec 31, 2020 | 663.60M | -181.20M | -21.45% |
Dec 31, 2019 | 844.80M | 61.70M | 7.88% |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Dec 31, 2014 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Swedish Orphan Biovitrum AB | 25.44B |
Getinge AB | 33.59B |
Sectra AB | 3.14B |
Camurus AB | 1.69B |
Medicover AB | 22.60B |
Vitrolife AB | 3.56B |
Bonesupport Holding AB | 814.46M |
Elekta AB | 17.72B |
Orexo AB News
- 10 days ago - Orexo announces positive topline data from clinical study of OX640 in subjects with and without allergic rhinitis - PRNewsWire
- 5 weeks ago - Orexo, Abera to develop nasal powder vaccines based on AmorphOX technology - Seeking Alpha
- 5 weeks ago - Orexo enters into collaboration with Abera to develop nasal powder vaccines based on the AmorphOX technology - PRNewsWire
- 3 months ago - Orexo initiates new study of OX640 in participants with allergic rhinitis - PRNewsWire
- 3 months ago - Orexo AB reports Q3 results - Seeking Alpha
- 3 months ago - Orexo´s Nomination Committee for the Annual General Meeting 2025 - PRNewsWire
- 5 months ago - Orexo to participate in Pareto Securities´ 15th Annual Healthcare Conference 2024 - PRNewsWire
- 6 months ago - Orexo shares new information on OX124, a high-dose naloxone rescue medication in development for opioid overdose - PRNewsWire